It may reduce lactate accumulation, delay the onset of muscle fatigue, and support faster recovery by optimizing metabolic pathways
The agency therefore evaluated the two substances separately and concluded that neither was adequately characterised for the proposed compounded use
Current GLP-1 Products and Uses The current market for GLP-1 agonists primarily consists of several key medications primarily indicated for the treatment of T2D or obesity
Due to the discovery of this activity in the brain, along with a higher prevalence of use for those between the ages of 30 and 64 years compared to other age groups, interest in applying GLP-1s to individuals with neurodegenerative conditions has grown, she said
Supports already healthy insulin sensitivity and weight management*
For women whose GLP-1 therapy is partly motivated by cardiovascular risk reduction, this distinction is not trivial